Rodríguez de Córdoba S, Subías-Hidalgo M, Pinto S, Tortajada A
[2014]. Genetics of atypical Hemolytic Uremic Syndrome (aHUS). Semin Thromb Hemost 40:422-430
Paixao-Cavalcante D, Torreira E, Lindorfer MA, Rodríguez de Córdoba S, Morgan BP, Taylor RP, Llorca O, Harris CL
[2014]. A humanised antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephrictic factors. J Immunol 192:4844-51)
Gayarre J., Durán-Trío L., Criado García O., Aguado C., Juana-López L., Crespo I., Knecht E., Bovolenta P. and Rodríguez de Córdoba S
[2014]. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease. Brain. 137:806-18.
Nozal P., Garrido S., Alba-Domínguez M., Espinosa L., Peña A., Rodríguez de Córdoba S., Sánchez-Corral P. and López-Trascasa M
[2014]. An ELISA assay with two monoclonal antibodies allows the estimation of free Factor H and identifies patients with acquired deficiency of this complement regulator. Mol. Immunol. 58:194-200
Poolpol K, Orth-Höller D, Speth C, Zipfel PF, Skerka C, Rodríguez de Córdoba S, Brockmeyer J, Bielaszewska M, Würzner R
[2014]. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58:77-84
Román-Ortiz E, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S
[2014]. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatric Nephrology 29:149-153
Liszewski MK., Kolev M., Le Friec G., Leung M., Bertram PG., Fara A., Subías M., Pickering MC., Drouet C., Meri S., Arstila P., Pekkarinen PT., Ma M., Cope A., Reinheckel T., Rodríguez de Córdoba S., Afzali B., Atkinson JP. and Kemper C
[2013]. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39:1143-1157
Pickering MC, D’Agati VD, Nester C, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Rodríguez de Córdoba S et al.
[2013]. C3 Glomerulopathy: consensus report. Kidney International 84:1079-89
Pelícano MB., Rodríguez de Córdoba S., Diekmann F., Saiz M., Herrero S., Oppenheimer F. and Campistol JM
[2013]. Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living-Related Kidney Transplantation. Transplantation 96:e26-e29
Alcorlo M, Tortajada A, Rodríguez de Córdoba S, Llorca O
[2013]. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin. Proc Natl Acad Sci USA 110:13504-9
Tortajada A, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O and Rodrígue de Córdoba S
[2013]. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123:2434-2446
Olivar R, Luque A, Naranjo-Gómez M, Quer J, García de Frutos P, Borrás F, Rodríguez de Córdoba S, Blom AM, Aran JM
[2013]. The a7b0 isoform of the complement regulator C4b-binding protein induces a semimature, anti-inflammatory state in dendritic cells. J Immunol 190:2857-72
Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Fremeaux-Bacchi V., Rodríguez de Córdoba S., Pinto S., Goodship TH., Alberti M., Ribes D., Valoti E., Remuzzi G., Noris M.;on behalf of European Working Party on Complement Genetics in Renal Diseases
[2013]. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475-486
Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S
[2013]. An update for atypical haemolytic uraemic síndrome: diagnosis and treatment. A consensus document (Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso) Nefrología 33:27-45
Rodríguez de Córdoba S, Tortajada A, Harris CL and Morgan BP
[2012]. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217:1034-1046
Paixao-Cavalcante D, López-Trascasa M, Skattum L, Giclas PC, Goodship TH, Rodríguez de Córdoba S, Truedsson L, Morgan BP, Harris CL
[2012]. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney International 82:1084-92
Kopp A, Strobel S, Tortajada A, Rodríguez de Córdoba S, Sánchez-Corral P, Prohászka Z, López-Trascasa M, Józsi M
[2012]. Atypical Hemolytic Uremic Syndrome-Associated variants and autoantibodies impair binding of factor H and factor H-Related protein 1 to Pentraxin 3. J Immunol 189:1858-67
Nozal P, Strobel S, Ibernon M, López D, Sánchez-Corral P, Rodríguez de Córdoba S, Józsi M, López-Trascasa M
[2012]. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clinical Kidney Journal 5:133-136
Harris CL., Heurich M., Rodríguez de Córdoba S. and Morgan P
[2012]. The complotype: dictating risk for inflamation and infection. Trends Immunol 33:513-521
Klionsky DJ., Rodríguez de Córdoba S. and 1269 others
[2012]. Guidelines for the use and interpretation of assays form monitoring autophagy. Autophagy 8:445:544
